Providing a new Dimension of Drug Discovery
MEET BINDKIN BIO
OUR STORY
Our co-founders struggled with difficult-to-isolate drug targets for years before realizing the solution to their drug discovery woes: invent a new approach. While partnering with leaders in AI drug design, our founders discovered the importance of beginning with native protein targets and experimentally validating all predicted drug interactions. We have utilized this approach in other forums to develop a number of molecules that are currently at various stages of clinical development, and we are deeply passionate about helping others in drug discovery do the same.
OUR VISION
By developing a novel approach to drug discovery, we boldly aim to find a cure for every disease. Traditional approaches to drug discovery have exhausted their capacity to identify hard-to-isolate targets. With the burgeoning approaches of computational biology and AI to expedite compound identification, we form alliances with these groups to provide experimental binding data for their lead compounds, thus accelerating the rate at which meaningful discoveries are made.
OUR TECHNOLOGY
Our approach is simple, yet refined. First, we have developed a proprietary protein isolation technique that promotes the likelihood of finding true binders from the very beginning. Next, we perform high-throughput, real-time, experimental binding kinetics assays on a target of interest and hundreds of predicted compounds simultaneously. We determine the affinity, k-on, and k-off binding parameters for all compounds in parallel, allowing our clients to prioritize lead compounds, and providing them physical data for pre-clinical drug packages. Computational biologists may also utilize experimental binding data with native targets to better improve their downstream binding predictions.